Enanta Pharmaceuticals has set up an 'at-the-market' agreement with Jefferies LLC to sell up to $75 million of its common stock over time, at market prices. Under the deal, Jefferies will act as sales agent and earn a 3% commission on each share sold, but Enanta is not required to sell any shares at all.

View Full Filing (SEC EDGAR)

View all Form 8-K filings

FAQ

Who are the top institutional investors holding ENANTA PHARMACEUTICALS INC (ENTA)?

Major stakeholders currently include Janus Henderson Group PLC ($47.7M), BlackRock, Inc. ($39.2M), Farallon Capital Management LLC ($36.3M). Based on the latest 13F filings, there are a total of 132 tracked investment funds and institutions maintaining positions in ENTA.

What is the overall institutional sentiment toward ENTA recently?

Institutional sentiment appears Bearish (Net Selling). During the most recent reporting quarter, the stock experienced a net outflow of $77.8M, driven by 68 managers accumulating shares while 56 reduced their exposure.

Which institutions have been selling or reducing their ENTA positions?

In the latest period, 35 funds trimmed their holdings, and 21 managers completely exited their positions. The aggregate reported sell value was $73.4M.

Are there any notable investors adding ENTA to their portfolios?

Yes, buying activity remains notable. 21 institutions opened new positions in {ticker}, and 47 existing holders added to their shares. The total reported buy value for the quarter amounted to $246.9M.